Erste Asset Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Erste Asset Management’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-8,800	Closed	-$947K	–	607
2023 Q1	$947K	Hold	8,800	–	–	0.02%	369
2022 Q4	$968K	Hold	8,800	–	–	0.02%	360
2022 Q3	$506K	Hold	8,800	–	–	0.01%	423
2022 Q2	$245K	Hold	8,800	–	–	0.01%	497
2022 Q1	$330K	Buy	+8,800	New	+$348K	0.01%	472

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Erste Asset Management's RXDX Position: Q2 2023 in Review

Erste Asset Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 8,800 shares — an estimated $947K sold.

Erste Asset Management first reported a position in RXDX in Q1 2022 and held it in 5 quarters. The position peaked at $968K in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Erste Asset Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Erste Asset Management sold 8,800 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $947K.
Erste Asset Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2022 and held it in 5 quarters.
Erste Asset Management's Prometheus Biosciences, Inc. Common Stock position peaked at $968K in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Erste Asset Management's 13F filing for Q2 2023, filed 26 Nov 2024.